Therapy for secondary arthropathies: From psoriasis and Reiter's disease to hemochromatosis;Therapie der sekundären arthropathien: Von der psoriasis über den morbus Reiter bis zur Hämochromatose

Internist

Volumn 47, Issue 12, 2006, Pages 1263-1268

  Godde A ^a   Muller Ladner U ^b  

^a Westpfalz Klinikum GmbH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Arthropathy; Hemochromatosis; Psoriatic arthritis; Reactive arthritis; Spondyloarthropathy

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; AZITHROMYCIN; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; DOXYCYCLINE; ERYTHROMYCIN; ETANERCEPT; GLUCOCORTICOID; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTHROPATHY; BACTERIAL INFECTION; BALANITIS; BURSITIS; CHONDROGENESIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL INFECTION; HEMOCHROMATOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ONSET AGE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REITER SYNDROME; REVIEW; SPONDYLOARTHROPATHY; TENOSYNOVITIS; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, REACTIVE; BIOLOGICAL PRODUCTS; DIAGNOSIS, DIFFERENTIAL; HEMOCHROMATOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OSTEOARTHRITIS; REITER SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845868753     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1754-0     Document Type: Review

References (23)

1. Abu-Shakra M, Gladman DD, Thorne JC et al. (1995) Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22: 241-245
2. Antoni CE, Kavanaugh A, Kirkham B et al. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52: 1227-1236
3. Blacki RL, O'Brien WM, Vanscott EJ et al. (1964) Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 189: 743-747
4. Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2482
5. Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37
6. Clegg DO, Reda DJ, Mejias E et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2013-2020
7. Clegg DO, Reda DJ, Weisman MH et al. (1996) Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2021-2027
8. Espinoza LR, Zakraoui L, Espinoza CG et al. (1992) Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 19: 872-877
9. Flagg SD, Meador R, Hsia E et al. (2005) Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 53: 613-617
10. Gladman DD, Antoni C, Mease P et al. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (Suppl 2): ii14-ii17
11. Kaltwasser JP, Nash P, Gladman D et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939-1950
12. Kvien TK, Gaston JS, Bardin T et al. (2004) Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 63: 1113-1119
13. Laasila K, Laasonen L, Leirisalo-Repo M (2003) Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 62: 655-658
14. Leirisalo-Repo M (2005) Reactive arthritis. Scand J Rheumatol 34: 251-259
15. Mease P (2004) TNF alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63: 755-758
16. Rihl M, Kellner H (2004) Die Arthropathie der hereditären Hämochromatose. Z Rheumatol 63: 22-29
17. Salvarani C, Macchioni P, Olivieri I et al. (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28: 2274-2282
18. Sarzi-Puttini P, Santandrea S, Boccassini L et al. (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19: S17-S20
19. Spadaro A, Riccieri V, Sili-Scavalli A et al. (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13: 589-593
20. Tavill AS (2001) Diagnosis and management of hemochromatosis. Hepatology 33: 1321-1328
21. Willkens RF, Williams HJ, Ward JR et al. (1984) Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27: 376-381
22. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. (2000) Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 59: 565-570
23. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. (2003) Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 62: 880-884